Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Equity Ratio (2018 - 2026)

Exagen filings provide 9 years of Equity Ratio readings, the most recent being 0.28 for Q1 2026.

  • On a quarterly basis, Equity Ratio rose 74.8% to 0.28 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.28, a 74.8% increase, with the full-year FY2025 number at 0.3, up 40.87% from a year prior.
  • Equity Ratio hit 0.28 in Q1 2026 for Exagen, down from 0.3 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.62 in Q1 2022 to a low of 0.16 in Q1 2025.
  • Median Equity Ratio over the past 5 years was 0.39 (2024), compared with a mean of 0.39.
  • Biggest five-year swings in Equity Ratio: tumbled 59.61% in 2025 and later skyrocketed 74.8% in 2026.
  • Exagen's Equity Ratio stood at 0.49 in 2022, then fell by 19.07% to 0.4 in 2023, then tumbled by 46.43% to 0.21 in 2024, then surged by 40.87% to 0.3 in 2025, then decreased by 7.64% to 0.28 in 2026.
  • The last three reported values for Equity Ratio were 0.28 (Q1 2026), 0.3 (Q4 2025), and 0.29 (Q3 2025) per Business Quant data.